[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 27 days · First seen · Last updated

Bombay High Court pharmaceutical pricing ruling

Overview

The Bombay High Court ruled against the National Pharmaceutical Pricing Authority (NPPA) regarding its ability to impose price ceilings on medicinal formulations. The court quashed a 2009 notification, determining it was ‘ultra vires’ the Drugs (Price Control) Order, 1995 (DPCO 1995).

In a specific case involving Pharmed Limited and its osteoarthritis treatment, Cartigen Forte, the court set aside a recovery demand of Rs 13.41 crore. The ruling clarified that while the NPPA may fix prices if manufacturers fail to provide necessary information, it must follow prescribed mechanisms and notify those prices in the official gazette according to DPCO factors, rather than applying blanket ceilings for multivitamin and mineral tablets to specific formulations.

Entities

Bombay High Court · Mumbai Port Authority · National Pharmaceutical Pricing Authority · Hapag Lloyd India Pvt. Ltd.

Timeline

  1. [BUSINESS] 2 sources
    Bombay High Court quashes NPPA pricing order and blocks recovery demand

    The Bombay High Court quashed an NPPA notification and blocked a Rs 13.41 crore recovery demand against Pharmed Limited, ruling that blanket price ceilings must follow DPCO 1995 procedures.

  2. [BUSINESS] 2 sources
    Bombay High Court quashes Mumbai Port Authority rent hikes

    The Bombay High Court has rejected retrospective rent increases by the Mumbai Port Authority, ruling that rate revisions must be fair, reasonable, and follow established compromise proposals.

Sources

darts.org.uk · liveLaw.in · medicaldialogues.in · taxguru.in